Mixed infections by different Trypanosoma cruzi discrete typing units among Chagas disease patients in an endemic community in Panama by Ledezma, Alexa Prescilla et al.
RESEARCH ARTICLE
Mixed infections by different Trypanosoma
cruzi discrete typing units among Chagas
disease patients in an endemic community in
Panama
Alexa Prescilla Ledezma1,2, Roberto Blandon3, Alejandro G. Schijman4,
Alejandro BenatarID
4, Azael Saldaña2,5, Antonio OsunaID1*
1 Institute of Biotechnology, Department of Parasitology, University of Granada, Granada, Spain, 2 Center
for Research and Diagnosis of Parasitic Diseases (CIDEP), Faculty of Medicine, University of Panama,
Panama, Panama, 3 Cardiology Service, Santo Tomas Hospital, Panama, Panama, 4 Laboratory of
Molecular Biology of Chagas Disease, Institute of Research in Genetic Engineering and Molecular Biology “Dr





Trypanosoma cruzi, the hemoparasite that causes Chagas disease, is divided into six Dis-
crete Typing Units or DTUs: TcI-TcVI plus Tcbat. This genetic diversity is based on ecobiolo-
gical and clinical characteristics associated with particular populations of the parasite. The
main objective of this study was the identification of DTUs in patients with chronic chagasic
infections from a mountainous rural community in the eastern region of Panama.
Methods
A total of 106 patients were tested for Chagas disease with three serological tests (ELISA,
rapid test, and Western blot). Molecular diagnosis and DTU typing were carried out by con-
ventional PCRs and qPCR targeting different genomic markers, respectively. As a control
sample for the typing, 28 patients suspected to be chagasic from the metropolitan area of
Panama City were included.
Results
Results showed a positivity in the evaluated patients of 42.3% (33/78); high compared to
other endemic regions in the country. In the control group, 20/28 (71.43%) patients pre-
sented positive serology. The typing of samples from rural patients showed that 78.78%
(26/33) corresponded to TcI, while 9.09% (3/33) were mixed infections (TcI plus TcII/V/VI).
Seventy-five percent (15/20) of the patients in the control group presented TcI, and in five
samples it was not possible to typify the T. cruzi genotype involved.
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Conclusions
These results confirm that TcI is the main DTU of T. cruzi present in chronic chagasic
patients from Panama. However, the circulation of other genotypes (TcII/V/VI) in this coun-
try is described for the first time. The eco-epidemiological characteristics that condition the
circulation of TcII/V/VI, as well as the immune and clinical impact of mixed infections in this
remote mountainous region should be investigated, which will help local action programs in
the surveillance, prevention, and management of Chagas disease.
Introduction
Chagas disease or American trypanosomiasis is a zoonosis spread from the southern USA to
approximately the Rı́o Negro in Argentina, whose causative agent is the hemoparasite Trypano-
soma cruzi [1]. This infection is transmitted to humans through different routes: i) by direct
contamination of the mucosa with the feces of the vector triatomine insects; ii) by ingesting
food contaminated with the feces of the vectors; iii) by congenital vertical transmission, and iv)
by blood transfusions or transplants of infected organs [1–4]. Currently, the estimated number
of patients infected with T. cruzi is 6–8 million and 120 million people are at risk of infection.
Chagas disease is the most important parasitic disease in Latin America and one of the most
common neglected diseases worldwide [5, 6]. The disease is characterized by an acute phase
that occurs in most cases asymptomatically or with nonspecific symptoms such as fever, malaise
and hepatomegaly [7, 8]. Mortality during this acute phase is low (<5%) and mostly linked to
myocarditis or meningoencephalitis [9, 10]. Approximately two months after the onset of infec-
tion, the chronic phase starts in 70% of the patients and there may be no symptoms even after
many years of evolution [11, 12]. The remaining 30% of chronic patients develop heart disease
of different degrees, representing the majority of deaths due to Chagas disease [4, 13]. In addi-
tion, 10% of these patients may also develop digestive alterations such as megacolon and megae-
sophagus as well as neurological alterations or a combination of both [4, 14, 15].
One of the possible causes of the diversity of the clinical manifestations of Chagas disease
has been attributed to the high genetic variability and the multiclonal character of the natural
populations of T. cruzi. [16]. This diversity has been demonstrated by different research groups
based on the marked variety among the different clones of the parasite [17]. Among the differ-
ences studied, histotropism, intracellular invasion and multiplication capacity, vector infectiv-
ity, drug sensitivity, morphology of trypomastigote forms, antigenic profile and potential
association to pathologies are mentioned. Different genotypic markers have allowed the cur-
rent identification of six discrete typing units, or DTUs, among the different T. cruzi isolates
plus a different variant identified as TcBat [18]. The enormous genetic variability found in this
species favors the appearance of these "strains", which complicates the classification according
to their pathology or other phenotypic peculiarities [19].
The geographical distribution of DTUs is particular, as well as their link with reservoirs,
transmission cycles, and diagnostic methods [16, 20, 21].
TcI is currently considered one of the parasite’s parental lineages [22]. Geographically, TcI
predominates in the Andes region, in Central and North America, Mexico [23–25], presenting
a sylvatic transmission cycle, mainly between marsupials and sylvatic triatomines [26–28].
This DTU is also associated with human infections reported from the United States [29],
Mexico, Central America [30, 31], and northern South America, having been detected in
patients with cardiomyopathies from Venezuela [32] and Colombia [33–37].
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DTUs (II, III, IV and V) have been found in vector insects, both in Colombia and Venezu-
ela as well as in the rest of South America [38, 39]. DTU II has been described as the cause of
parasitation in humans in both acute and chronic cases, as well as in vectors from Colombia,
and this DTU is considered to correspond to a primarily domiciliary cycle [40, 41].
Chagasic infection has been known in Panama since 1930 [42, 43]. In 2005, the Pan-Ameri-
can Health Organization (PAHO) estimated, based on official data, that the seroprevalence in
this country was 0.01% [44]. Subsequent studies located the rural regions near the Panama
Canal as the areas with the highest number of cases [43, 45, 46]. Recent research confirmed
that the infection is also common in other areas located west and east of the capital city [47–
49]. In contrast, there are still remote rural communities with the appropriate eco-epidemio-
logical conditions for the transmission of Chagas disease where correct epidemiological sur-
veillance has not been implemented [49–51]. From 2007 to 2017, an average of 56 annual cases
of Chagas disease were reported in Panama, for a total population of about 4,159,000 inhabi-
tants [52]. Although these figures are below those reported in other countries of Central and
South America [49], chagasic infection in Panama is still an important public health concern
[53]. In Panama, the main Chagas disease vector is Rhodnius pallescens, a triatomine present in
the Attalea butyracea palm, which is often found in peridomestic areas of endemic communi-
ties and that invades nearby dwellings, but does not settle inside them [37, 54–56]. On the
other hand, the clinical characteristics related to Chagas disease in Panama involve heart dis-
eases similar to those described in other regions of the continent [25, 57, 58]. However, until
now no clinical cases of Chagas disease with digestive pathologies have been described in Pan-
ama [42, 59].
The genetic variants of circulating T. cruzi in vectors and acute patients have been partially
investigated in Panama [25, 49]. Yet, in these preliminary studies, only T. cruzi TcI was
detected [57, 60] as well as the typification of a T. cruzi isolate from a rural area of the Arraiján
district [17].
Currently, there are no investigations being carried out aimed at the identification of T.
cruzi DTUs from blood samples from Panamanian patients. This type of study reflects the
genetic diversity of parasites in natural infections without the need for their isolation or expan-
sion, a particularly difficult situation in chronic patients with very low parasitemias [57, 61].
Moreover, genotyping of cultured parasite isolates may lead to misidentification of minor
genotypes in mixed infections, since populations that grow at a higher rate are more likely to
be detectable by the available typing approaches.
Although information on the distribution of DTUs in different geographical areas is
increasing, confirmed association with the clinical manifestations and epidemiology of Chagas
disease is limited. As there is a new focus of Chagas disease in Panama, it is relevant to propose
ecobiological studies of T. cruzi infection in this region of the country aiming to improve sur-
veillance and control measures.
The main objective of the study was the direct identification of T. cruzi DTUs in blood sam-
ples from chronic chagasic patients resident in this new highly endemic rural community, “Las
Margaritas”, Chepo district, Panama province, in comparison to the DTUs detected in Chagas
disease patients in the metropolitan area of Panama City, representative of T. cruzi infected
people in the main endemic regions of the country.
Materials and methods
Ethical statement
All protocols involving human subjects were approved by the Bioethics Committee of Santo
Tomás Hospital in Panama City and were assigned the identification code No. 2015–310 V1. A
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total of 106 enrolled patients signed written or oral informed consent forms. Individuals who
could not read, stamped their fingerprint on the document, in the presence of two witnesses.
Acceptance of informed consent was carried out before the study activities were initiated and the
analysis was performed according to the approved guidelines. Individuals over 18 years of age
signed the consent form and responded to the social and epidemiological questionnaire. Parents
and/or guardians of children and youth under 18 years of age provided their written consent for
the collection of blood and responded to the social and epidemiological questionnaire.
Patients and sampling
The study was carried out between April 2016 and January 2017 in two different epidemiologi-
cal settings: 1) a small rural community (Charare), located in a mountainous area, in the town-
ship of Las Margaritas, Chepo district, Panama province (coordinates 9.243640, -79.059162)
(Fig 1).
The total population of Charare is approximately 250 inhabitants. Sampling was done for
convenience; all inhabitants were invited to participate through messages on a local radio sta-
tion. The total number of samples studied was 106; 73.58% (78/106) corresponding to resi-
dents of Charare and 2) a total of 28 suspected chagasic patients diagnosed in the metropolitan
area of Panama City, of whom 20/28 (71.42%) presented positive serology. All these patients
also signed the informed consent form. This group of patients represents the T. cruzi infected
population from the main endemic regions of the country, as many of whom travelled to Pan-
ama City to be admitted to hospitals. Therefore, their parasitic populations are representative
of the main circulating genetic variants of the parasite in the country. All hospitalized cases
Fig 1. The locations of seropositive patients: Chararé community, Las Margaritas district, Chepo district, Panama province. The Map has been drawn by the authors,
as well as the photos that are original.
https://doi.org/10.1371/journal.pone.0241921.g001
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with positive serology had been diagnosed due to their clinical manifestations: repolarization
disorders, atrioventricular block, bradycardia, and conduction disorder. The diagnoses were
made in the tertiary care hospitals included in the study (Santo Tomás Hospital, Dr. Arnulfo
Arias Madrid Hospital Complex, and Omar Torrijos Herrera Hospital for Pediatric Special-
ties), using ARCHITECT System1 Chagas assay (Abbott, Germany). Reconfirmation of T.
cruzi infection was carried out in all rural and urban cases, using at least two immunological
tests as described below. All urban patients had undergone specialized medical evaluation in
the respective hospitals. In the case of patients from the rural community, once the serological
diagnosis was made, they were clinically evaluated at the Regional Hospital of Chepo district,
where they were evaluated and treated according to the clinical characteristics found.
The total number of patients with positive serology evaluated in the study was 53, and 20 of
whom were treated at third-level hospitals in Panama City distributed as follows: 13 at the Car-
diology service of Santo Tomás Hospital, four diagnosed at the Blood Bank of the Social Secu-
rity Fund and two at the Infectology Outpatient Clinic of the Dr. Arnulfo Arias Madrid
Hospital Complex of the Social Security Fund.
Thirty-three of the seropositive patients corresponded to the rural areas, all of whom per-
manent residents in the community of Chararé.
All individuals who agreed to participate in the study had two venous blood samples taken.
The first sample of approximately 5 ml was collected in a Vacutainer™ EDTA vacuum blood
collection tube for molecular assays. The blood sample was mixed 1:1 with a 6M guanidine
hydrochloride solution (Sigma, St. Louis, USA.) and 200 mM EDTA, pH 8.0 (GEB) [62].
These samples were kept at laboratory temperature (22˚ C) for at least 4 days. For the second
sample, BD Vacutainer ™ Venous Blood Collection Tubes were used (Vacutainer Plus ™ Glass
Serum Tube), and 5 ml of blood were taken. After the clot formed, each tube was centrifuged
at 1,500 x g for 10 min and approximately 2.0 ml of serum were collected to carry out the dif-
ferent serological tests.
Serological tests
The presence of anti-T. cruzi antibodies in the different samples was confirmed by commercial
tests of recombinant ELISA Chagatest, Wiener Lab, Argentina. Briefly, 10 μL of each serum
sample were used and diluted with 200 μL of the sample diluent, then incubated for 30 min at
37˚C, and washed 5 times with diluted 1:5 washing buffer. Next, 50 μL of the conjugate (perox-
idase-conjugated anti-human (goat) immunoglobulins) were added and incubated for 30 min-
utes at 37˚C. Subsequently, 5 washes were carried out with 300 μL thereof and the residue was
completely aspirated. After the washings were completed, 50 μL of each of the developers were
added: A (hydrogen peroxide 60 mmol / l in citrate buffer 50 mmol / L pH 3.2) and B (tetra-
methylbenzidine (TMB) 0.01 mol / l in 0.1 N hydrochloric acid) by incubating the wells for 30
minutes at room temperature. Finally, 50 μL of stop solution (2N sulfuric acid) were added
and the reading was carried out at 490 nm in a Multiskan1 Spectrum reader (Thermo Fisher
Scientific, Finlandia). Both negative (non-reactive, inactivated serum dilution) and positive
(inactivated serum dilution containing antibodies against T. cruzi) samples were performed in
triplicate.
The SD Bioline Chagas AB Rapid test (Abbott, Germany) was used, following the manufac-
turer’s instructions. Briefly, 100 μL of the study serum were added to the sample well and
50 μL of the assay buffer (100 mM Tris-CI (5 ml) were added. It was then incubated at room
temperature for 15 minutes. The test was read visually after 15 minutes. Any positive sample
with the Chagas Ab SD Bioline Rapid Test was confirmed with alternate test methods. As a
complementary assay, an immunoblot test of a Panamanian isolate of T. cruzi was used
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following the methodology described [63]. Briefly, each membrane was incubated with a 1:100
dilution (in milk solution) of the sera of the evaluated patients. Incubation was carried out
under shaking, at room temperature, overnight, in 2.5ml tubes containing the nitrocellulose
strip and 700μl of the respective serum dilution. The strip was then washed 3 times with PBS
and incubated with human anti-immunoglobulin conjugate (DAKO IgG, IgM and IgA)
diluted at 1:700 in PBS for one hour. Then, each strip was washed 3 times with PBS, before
adding the substrate-chromogen (H2O2, PBS, NiCl, diaminobenzidine); the reaction was
stopped with tap water, after approximately 10 minutes. The strips were photographed for the
interpretation of the generated profiles.
The patients were considered positive when they showed positivity in at least two of the
three immunological tests.
A questionnaire containing demographic information and indicators of knowledge, atti-
tudes and risk factors for the transmission of Chagas disease as well as the mode of transmis-
sion, main clinical characteristics and biology of the vector (habits and ecotope, among others)
was given to each patient with positive serology for chagasic infection (S1 Questionnaire). An
anonymous identification number was used to identify information in the questionnaires.
DNA extraction
DNA extraction from blood samples was carried out using a commercially available kit (High
Pure PCR Template preparation kit, Roche Applied Science), following the manufacturer’s
instructions. For the extraction of DNA, 500 μl of GEB were used and finally eluted in 100 μl
ultrapure water. The extracted DNA was stored at -20˚C until further analysis [64, 65].
Polymerase chain reaction for the detection of Trypanosoma cruzi
Trypanosoma cruzi DNA detection was performed by PCR analysis in a CFX96 ™ Real-Time
System thermal cycler CFX-96 Real Time System (Bio-Rad Laboratories). The reaction mix-
ture was made with a 1X Go Taq1 flexi buffer amplification buffer, 25 mM dNTPs, 2.5 mM
MgCl2, 1.0 U of Go Taq1 (Promega, USA), 10 pmol of specific primers 121 (AAATAATGT
ACGGGKGAGATGCATGA) and 122 (GGTTCGATTGGGGTTGGTGTAATATA) according to the
methodology described [66]. The amplification conditions consisted of two cycles, each of 1
min at 98˚C and 2 min at 64˚C, followed by 33 cycles of 1 min at 94˚C, and 1 min at 64˚C,
before a final extension at 72˚C for 10 min. A DNA sample from T. cruzi tripomastigote forms
in culture was used as a positive control, and a negative control was run without a DNA sam-
ple. PCR products were analyzed by agarose gel electrophoresis with SYBR Green and UV
visualization in ChemiDoc MP Imaging System Bio Rad. A 330-bp product was considered
indicative of the presence of the kinetoplastid DNA (kDNA) of T. cruzi.
Genotyping assays of T. cruzi by PCR assays
For the identification of the T. cruzi DTUs detectable in the blood samples, a series of PCRs
targeting different genomic markers was carried out, following the PCR-based algorithm
reported by Burgos and co-authors [65], as described in S1 Table and S1 Fig. The DTU typing
algorithm included the following T. cruzi genomic targets:
(1) the Spliced Leader intergenic region (SL-IR PCR) was used to distinguish T. cruzi I (150
bp), II, V, and VI (157 bp) from T. cruzi III and IV (200 bp); (2) first round and hemi- nested
SL-IR-I was used to identify T. cruzi I DTUs (475 bp and 350 bp, respectively), and first round
and hemi-nested SL-IR-II was used to identify T. cruzi II, V, and VI DTUs (425 bp and 300 bp,
respectively); (3) hemi-nested PCR of 24S α- ribosomal DNA was used to distinguish T. cruzi
V (125 or 125 + 140 bp) from T. cruzi II and VI (140 bp); and (4) hemi- nested real-time PCR
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targeting the A10 fragment was used to discriminate T. cruzi II (580 bp) from T. cruzi VI (525
bp). Samples that yielded positive SL-IR-II PCR results but negative 24S α-ribosomal DNA
PCR results were reported as T. cruzi II, V, or VI (II/V/VI). Samples that amplified the 140-bp
24Sα-rDNA fragment but negative results of real-time PCR targeting A10 were reported as T.
cruzi II or VI, as described [65].
Results and discussion
Of the 78 rural patients evaluated, 42.3% (33/78) were seropositive for T. cruzi infection. This
percentage suggests the existence of a high prevalence of chagasic infection in this rural area of
Panama, when compared to the percentages found in recent studies in other endemic areas,
where lower seroprevalences were demonstrated [48]. However, this high frequency of chaga-
sic infection is consistent with sero-epidemiological studies carried out in other near endemic
regions. As described by Anez et al. (2004), rural regions of Venezuela have a seropositivity of
56.8%, and in the Arauca region in Colombia, 21.6% of 0 to 14 year-old children tested positive
for chagasic infection [32, 67, 68].
In 2010, the Department of Vector Control of the Ministry of Health of Panama reported the
presence of the two main vectors of Chagas disease (R. pallescens and Triatoma dimidiata) in
the community of Chararé. Around that time, the first cases of Chagas disease were diagnosed
in the community. However, the genetic characteristics of circulating T. cruzi populations in
the area have hitherto not been studied. This mountainous area is located in a remote region of
difficult access, its inhabitants share low eco-epidemiological and socioeconomic characteristics
that predispose the transmission of multiple pathogens, including T. cruzi (Table 1) [48].
All seropositive cases detected in the Chararé region can be considered chronic Chagas dis-
ease patients. Prior to sample collection, none of the patients reported fever or clinical signs
that could suggest the acute phase of the disease. T. cruzi infection was characterized in these
patients by means of a kDNA-based PCR test; 90% out of 20 urban patients were kDNA-PCR
positive and 100% of patients from Chararé were kDNA-PCR positive. Genotyping of DTUs
of these patients’ blood samples was carried out from the same DNA extracts without previous
knowledge of the kDNA-PCR result. In fact, kDNA-PCR negative samples did not amplify
genes used for DTU typing. Among kDNA-PCR positive samples, it was possible to identify
DTUs in 15/18 and 29/33 samples from rural and urban localities (Table 2) and only after
amplification of the T. cruzi SL-IR I and SL-IR II genes as molecular targets, whereas the other
genotyping markers gave non-detectable results. Thus, distinction could only be made
between TcI, and Tc II/V/VI DTU groups. These SL-IR I and II based PCR procedures showed
that in Chararé, 78.78% of patients were infected with DTU I strains, while 9.09% corre-
sponded to mixed DTU I plus DTU II/V/VI infections. In four of these samples (12.12%), the
corresponding DTU group could not be determined (Table 2). The failure to genotype some
of the tested samples was probably due to low parasitic loads, below the detection limits of the
SL-IR I and II PCR methods (S1 Table) [65, 69]. The same limitation can be suspected for the
other genotyping markers that gave undetectable findings.
The kDNA-PCR analysis of seropositive samples from urban chagasic patients, was positive
in 18/20 (90%) of the samples. Fifteen of the samples, equivalent to 75%, were infected with Tc
I populations and in five samples, it was not possible to typify the T. cruzi DTU involved.
DTUs III/IV were not detectable in these populations. From the PCR positive data, it can be
deduced that the analyzed blood samples from the chronic patients present circulating trypo-
mastigote forms of the parasite as well as amastigote forms resulting from the death and rup-
ture of infected cells, or there is DNA contamination from the kinetoplast of the parasite due
to the destruction of the parasite forms and the consequent release of the kDNA. Among
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seropositive patients diagnosed in urban hospitals (ARCHITECT System Chagas assay),
71.42% (20/28) presented a clinical profile with heart disease evidenced by echocardiogram
and chest radiography, and the data of rural endemic community patients were sent to the
health services for their clinical evaluation after serological diagnosis. Asymptomatic patients
were found in 30.30% (10/33), with some degree of heart disease 18.18% (6/33), in 51.51% (17/
33) the clinical evaluation was not performed (S2 Table).
In some samples in which the serological tests showed discrepancies in the positivity results,
the PCR verification of the presence of kDNA confirmed infection. Thus, this technique
should be incorporated in the diagnostic confirmation of T. cruzi infection.
Surveys carried out, both in urban and rural areas showed that among the evaluated
patients 53% were male, including 6 children below 15 years of age. With reference to
Table 1. Sociodemographic characteristics of the interviewees by area of residence.
Variable Total n = 53 Urban Patients n = 20 Rural Patients n = 33
n % n % n %
Sex
Female 25 47.2 7 40.0 18 54.5
Male 28 52.8 13 60.0 15 45.5
Age
Less than 25 years 10 18.9 0 0.0 10 30.3
From 25 to 39 years 18 34.0 9 45.0 9 27.3
From 40 to 59 years 17 32.1 9 45.0 8 24.2
Over 60 years 8 15.0 2 10.0 6 18.2
Total 53 100.0 20 100.0 33 100.0
Time of Residence Total n = 43 Urban Patients n = 20 Rural Patients n = 23
Less Than 1 year 3 7.0 2 10.0 1 4.3
From 2 to 5 years 5 11.6 5 25.0 0 0.0
More than 5 years 35 81.4 13 65.0 22 95.7
Education
No degree 5 11.6 0 0.0 5 21.7
Primary 21 48.8 7 35.0 14 60.9
High School 10 23.3 6 30.0 4 17.4
Tertiary 3 7.0 3 15.0 0 0.0
University superior 4 9.3 4 20.0 0 0.0
Occupation
Employee 13 30.2 6 30.0 7 30.4
Self-employed 12 27.9 6 30.0 6 26.1
Domestic work 11 25.6 0 0.0 7 30.4
Unemployed 4 9.3 5 25.0 3 13.1
No answer 3 7.0 3 15.0 0 0.0
Household residents
1 4 9.3 2 10.0 2 8.7
From 2 to 5 15 34.9 8 40.0 7 30.4
More than 5 people 24 55.8 10 50.0 14 60.9
Patients in the home
1 38 88.4 20 100.0 18 78.3
2 3 7.0 0 0.0 3 13.1
3 1 2.3 0 0.0 1 4.3
4 1 2.3 0 0.0 1 4.3
https://doi.org/10.1371/journal.pone.0241921.t001
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socioeconomic data, it was evident that 100% of the rural patients knew about the transmitting
insects of Chagas disease and, based on the level and quality of the dwelling, had had repeated
contact with these insects. An outstanding finding was the fact that up to four seropositive
patients living in the same family unit were reported in the Chararé community (Table 1).
This contrasts with the urban patients, of whom everyone knew both, the disease and the insect
vector, but most of whom did not remember direct contact with the insect. The diagnosed
urban patients reported being the only infected individuals in their family units after all their
family members had been assessed. In all cases, regular periodic stays and overnight stays had
been reported in rural areas, respectively, areas with high Atallea palm density.
The rural community of Chararé is a community with marked poverty and without easy
land access, having scarce health resources, and living on subsistence economy based on agri-
culture, with 56.52% working on their own or in domestic work, and only 30% are salaried. A
high percentage, 95.65% of those surveyed had been living in the community for more than 5
years, living with a large variety of domestic/wild animals and frequently exposed to the pres-
ence of triatomine vectors. Most of its inhabitants (82.60%) had received basic education (pri-
mary and secondary), while 21.73% had no education, being unaware of many aspects of the
symptomatology, pathology, treatment or control of the disease (Table 1).
The significant levels of seropositivity found in this study should be considered by the coun-
try’s health authorities in order to implement better surveillance, prevention, and control pro-
grams for this parasitosis.
As for the urban population, 65% had received basic education, and 35% had attended
higher education or university, thus having a better understanding of the relevant aspects of
Chagas disease. The salaried population is 30%, evidencing in both groups and with high per-
centage of large families (Table 1).
The clinical manifestations of chagasic infection in Panama are primarily cardiac during
both the acute and chronic phases of the disease, with no evidence that the digestive form
develops during the later stages of infection [43].
The pattern of Chagas disease in Panama seems to be similar to that of other regions
such as Venezuela, Colombia and Central America, where cardiac manifestations prevail
[17, 70, 71]. In this sense, and based on the diverse ecobiological conditions existent in Pan-
ama, it is likely that, as in other regions of northern South America, DTUs other than TcI
are in circulation, both in vectors and in reservoirs. The ecoepidemiological conditions, not
fully known in this region, could explain the existence of different DTUs. The import of
Table 2. Serological and PCR-based findings in the two patient groups studied. Patients screened with the different methodologies in the two study groups. The pres-
ence of 5.6% (3/53) of patients with mixed DTU (DTU I and II/V/VI) is clearly presented.
Samples Urban Patients Rural Patients Total
Total tested samples 28 (26.42%) 78 (73.58%) 106 (100%)
Anti-T. cruzi seroreactivity 20 (71.43%) 33 (42.30%) 53 (50%)
kDNA-PCR positivity 18/20 (90%) 33/33 (100%) 51/53 (96.22%)
DTU PCR positivity 15/20 (75%) 29/33 (87.88%) 44/53 (83.01%)
Tc I 15/20(75%) 26/33 (78.78%) 41/53 (77.35%)
Mixed -- 3/33 (9.09%) 3/53 (5.66%)�
Tc I + Tc II/V/VI
Untyped DTUs# 5/20 (25%) 4/33 (12.12%) 9/51 (17.64%)
� The presence of 5.6% (3/53) of patients with mixed DTU (DTU I and II/V/VI) is clearly presented.
# The numbers include those cases with nondetectable kDNA-PCR findings plus those kDNA-PCR positive samples that gave nondetectable results in the PCRs
performed for DTU genotyping.
https://doi.org/10.1371/journal.pone.0241921.t002
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infected animals or the arrival of foreign vectors is much more complex since the area is
remote and difficult to access. A study in Colombia [72] detected the presence of esophageal
achalasia associated with Chagas disease, induced by TcI, present in patients diagnosed with
this pathology. On the other hand, in Colombia, chagasic patients with mixed cardiac and
gastrointestinal involvement were reported, and the genotyping of the tissue samples
showed both, TcI in the affected esophagus and TcII in the heart samples [73]. Similarly,
mixed infections in insects involving different DTUs (DTU II, III and IV) have been
reported [38]. Although in Colombia, DTU I has been reported in most patients, insect vec-
tors and reservoirs, the existence of TcII strains has also been reported in chronic chagasic
patients [73]. Likewise, in Venezuela, in ecotopes similar to those evaluated in Panama,
human infections caused by TcI and TcII strains and mixed infections in cardiac tissue have
been detected with DTUs I, II, III and IV strains [38, 74].
Similar studies suggest that genetically related populations of T. cruzi possibly exist in
the same or adjacent geographic areas and could be involved in determining the develop-
ment of the same clinical form of the disease. In a study carried out by Vago et al. (2000),
multiclonal strains in the heart and esophagus were found, evidencing the first data of possi-
ble human differential tissue tropism [75]. Among the three patients with mixed infections
(cases 31, 33 and 36) S2 Table, all were residents of Chepo, Las Margaritas and two of them
(cases 31 and 36) had cardiac manifestations, while the remainder (case 33) was asymptom-
atic. As the latter patient was only 14 years old when tested, it cannot be ruled out that, if
not treated, she would have developed cardiac disease. On the other hand, taking into con-
sideration the histotropism hypothesis (48), we cannot discard that the other patients stud-
ied harbor non-Tc I genotypes that could not be detected in peripheral blood in the samples
taken. Follow-up of patients residing in this locality, and especially patients belonging to the
families exhibiting mixed infections, would be of much interest in order to find out if geno-
types other than TcI may emerge at different lifetime periods along the natural history of
their chronic infection.
Research carried out in the Gran Chaco, Argentina, revealed mixed infections of human
TcV / TcVI and canine TcI / TcVI in rural areas, demonstrating significant associations
between TcV with humans and TcVI with dogs. They also found TcIII, TcI and TcV in dogs
and for the first time described TcIII in humans in this area, suggesting that there is contact
with wild mammals during hunting or that Tc III may be involved in the domestic cycle [76].
On the other hand, experimental studies carried out in dogs with T. cruzi Y (TcII) or Col
(TcI) have shown that infection by T. cruzi can be caused by different strains of different
DTUs that favor variable clinical forms of chronic Chagas disease, so that the immune
response and cardiac lesions can be evaluated. The Col (TcI) strain escapes the host’s acute
immune response, goes unnoticed by peripheral blood mononuclear cells, and therefore para-
sitizes organs more rapidly. In contrast, strain Y (TcII), the specific immune response begins
in the acute phase, which helps control myocardial injury in the early chronic phase [77]. Simi-
larly, experimental studies in mice refer to Chagas disease heterogenicity from diverse aspects
such as organ damage, parasite tropism, immune response, infection phase and strain [78–80].
Studies performed by Mining and coworkers [19], using whole genome tiling arrays for
comparative genome analysis of cultured parasite stocks, have revealed that there is much
more genotypic diversity among T. cruzi strains than can be understood using traditional typ-
ing methods. In particular, within Tc I, their typing results, together with studies based on
microsatellite analyses of Tc I strains [81], indicate that that there is substantially more genetic
diversity among Tc I strains than there is among other DTUs. Accordingly, further investiga-
tion in isolates from Panama would be needed to assert the intra-DTU variability of circulating
Tc I genotypes and their possible transmission cycles.
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Conclusions
Our findings in Chararé confirm TcI as the main circulating DTU in chronic Chagas disease
patients from Panama and describe, for the first time, minoritary cases of coinfections with
parasite populations belonging to non-Tc I genotypes, such as Tc II, Tc V or Tc VI. The pres-
ence of chagasic infections with mixed genetic variants of the parasite in rural areas justifies
eco-epidemiological and clinical studies in this new endemic area for Chagas disease in Pan-
ama. These investigations should aim to describe the eco-epidemiological implications of the
circulation of these DTUs that coinfect together with Tc1 this region of the country, either as a
result of the entry of vectors, wild or domestic mammalian reservoirs, or through human
migration in this region framed in the natural passage between South America and Central
America. It is also a pending task to determine if these new genetic variants of T. cruzi detected
are native.
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on emergent Chagas disease. Huete-Pérez JA, editor. PLoS Negl Trop Dis. 2009 Sep 1; 3(9):e510.
21. Bhattacharyya T, Mills EA, Miles MA. Prospects for T. cruzi lineage-specific serological surveillance of
wild mammals. Acta Trop. 2015 Nov 1; 151:182–6. https://doi.org/10.1016/j.actatropica.2015.06.017
PMID: 26116784
22. Sturm NR, Campbell DA. Alternative lifestyles: The population structure of Trypanosoma cruzi. Acta
Trop. 2010 Jul 1; 115(1–2):35–43. https://doi.org/10.1016/j.actatropica.2009.08.018 PMID: 19695212
23. Cortez M, Atayde V, Yoshida N. Host cell invasion mediated by Trypanosoma cruzi surface molecule
gp82 is associated with F-actin disassembly and is inhibited by enteroinvasive Escherichia coli.
Microbes Infect. 2006 May 1; 8(6):1502–12. https://doi.org/10.1016/j.micinf.2006.01.007 PMID:
16697683
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29. Roellig DM, Brown EL, Barnabé C, Tibayrenc M, Steurer FJ, Yabsley MJ. Molecular typing of Trypano-
soma cruzi isolates, United States. Emerg Infect Dis. 2008 Jul; 14(7):1123–5. https://doi.org/10.3201/
eid1407.080175 PMID: 18598637
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